Draft guidance from the National Institute for Health and Care Excellence recommends using the XVIVO lung-perfusion system across the NHS for four years while its effectiveness and value are assessed, a pre-cutoff evidence stage that remains short of final guidance, national delivery, or completed treatment results. [1]

The machine warms and ventilates donated lungs while circulating a fluid that mimics blood plasma, allowing transplant teams to assess function and attempt treatments such as draining fluid or addressing infection before deciding whether an organ can be used.

NICE estimates that the process could rescue four in five donated lungs now unused, but an estimate about eligibility cannot be counted as hundreds of completed transplants, fewer waiting-list deaths, longer survival, fairer access among centers, or value for money.

The Guardian reports that 170 patients, including six children, were waiting for lungs and that only 23% of donated lungs were used, while also noting that organ quality is not the only constraint because staffing and theatre capacity can cause declines.

Four years of evidence collection should therefore measure utilization, adverse events, transplant activity, survival, pediatric and regional access, staffing, theatre time, and cost; until those receipts arrive, the honest news is that NICE has backed a test of a promising machine rather than delivered its promised result.

-- NORA WHITFIELD, Chicago